Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
XTalks
AUGUST 17, 2020
For their second molecule, the peptide was swapped out with a Wilm’s tumor 1 (WT1) peptide, and the third one has a KRAS peptide. Targeting WTI and KRAS-Driven Tumors. The third asset in the pipeline targets a mutated epitope of KRAS, which is a primary tumor driver. The second molecule from Cue Biopharma is known as CUE-102.
98 
Let's personalize your content